By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

Company News
Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) Receives Expanded FDA Approval In Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival To More Patients 10/12/2015 11:11:43 AM
LabCorp (LH) To Offer New PD-L1 Test For Bristol-Myers Squibb (BMY)’s OPDIVO Following Collaboration In Clinical Trial 10/12/2015 8:46:52 AM
Quest Diagnostics (DGX) Introduces Dako (A)'s PD-L1 Complementary Diagnostic Test To Support Bristol-Myers Squibb (BMY)'s OPDIVO Anti-PD-1 Therapy For Non-Squamous Non-Small Cell Lung Cancer 10/12/2015 6:57:39 AM
Bristol-Myers Squibb (BMY) Release: FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs 10/6/2015 11:29:24 AM
Bristol-Myers Squibb (BMY) Snags FDA's Priority Review for Daklinza SNDAs 10/6/2015 6:03:12 AM
Bristol-Myers Squibb (BMY) Announces FDA Regulatory Filing Update For The Opdivo+Yervoy Regimen In Patients With Previously Untreated Advanced Melanoma 9/28/2015 2:05:55 PM
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Superior Overall Survival In A Phase 3 Trial Compared To Standard Of Care In Patients With Previously Treated Advanced Renal Cell Carcinoma 9/28/2015 2:02:35 PM
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Demonstrates Long Term Survival Benefit In Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer In Checkmate -057 9/28/2015 1:32:15 PM
Bristol-Myers Squibb (BMY) Launches Working Together For Patients, A Program Highlighting The Company’s Commitment To Patients 9/28/2015 12:33:34 PM
Bristol-Myers Squibb (BMY) And H. Lee Moffitt Cancer Center & Research Institute Enter Into A Collaboration Agreement As Part Of U.S. Immuno-Oncology Rare Population Malignancy Program 9/25/2015 8:39:22 AM